MedTrace Logo

Nebulized Lidocaine, Dexmedetomedine and Their Combination in Direct Laryngoscopy Surgery

NCT04659057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-07-13

No results posted yet for this study

Summary

Direct laryngoscopy (DL) procedure is typically done under general anaesthesia as a day case. It is a short but irritating.Various drugs and drug combinations have been used to attenuate stress response to DL.Administrating nebulized form of drugs can be effective with less systemic side effects. The primary outcome of this study is to compare the effect of premedication with nebulized lidocaine, dexmedetomidine, combination of both to placebo on haemodynamic response during DL procedures.

Conditions

  • Hemodynamic Instability

Interventions

DRUG

Nebulized Lidocaine

will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).

DRUG

Nebulized dexmedetomidine

will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).

DRUG

Nebulized lidocaine and dexmedetomidine

will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.

OTHER

Placebo

will receive nebulized saline 0.9% (5 ml) as control group.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hala S El-Ozairy, MD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-12
Primary Completion
2021-07-11
Completion
2021-07-11

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04659057 on ClinicalTrials.gov